Evidence map›Paper›PMID 38898018›Full record

Trial reportNature communications2024

Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial.

Hongli Gong, Shu Tian, Hao Ding, Lei Tao, Li Wang, Jie Wang, Tian Wang, Xiaohui Yuan, Yu Heng, Ming Zhang and 5 more

Erratum issued 2 registry-linked trialsAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04156698 phase2unknown statusnot on this map

A Phase II, Single-center, Open-label, Single-arm Study of Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

TypeinterventionalSponsorEye & ENT Hospital of Fudan UniversityRan2020 to 2026Enrolled51ConditionsHypopharyngeal Carcinoma, Immunotherapy, ChemotherapyArmsDocetaxel, Cisplatin, Capecitabine, Camrelizumab
NCT07791602 phase2active not recruitingnot on this mapstarted 2026, after this paper: background citation

Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy (IDEAL-RT) in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Multicenter, Prospective, Phase II, Randomized Non-Inferiority Controlled Trial

TypeinterventionalSponsorCancer Institute and Hospital, Chinese Academy of Medical SciencesRan2026 to 2032Enrolled180ConditionsHead and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer, HNSCCArmsCamrelizumab, Platinum-based Chemotherapy plus PD-1 inhibitor, De-escalated Radiotherapy, Standard Radiotherapy
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Comparison of induction chemotherapy followed by concurrent chemoradiotherapy versus neoadjuvant chemotherapy followed by surgery and (chemo)radiotherapy in locoregionally advanced hypopharyngeal carcinoma: a prospective cohort study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Systemic therapy for laryngeal carcinoma.Frontiers in oncology · 2025
    Review
  18. Article
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Hongli Gong *ENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Shu Tian *Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Hao DingDepartment of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Lei TaoENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Li WangDepartment of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Jie WangDepartment of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Tian WangDepartment of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Xiaohui YuanENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Yu HengENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Ming ZhangENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Yong ShiENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Chengzhi XuENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Chunping WuENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Shengzi WangDepartment of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China. shengziwang@fudan.edu.cn.
Liang ZhouENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China. zhoulent@126.com.ORCID http://orcid.org/0000-0002-8588-2959

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This phase II trial aimed to determine the efficacy and safety of induction chemoimmunotherapy of camrelizumab plus modified TPF in locally advanced hypopharyngeal squamous cell carcinoma (LA HSCC) (NCT04156698). The primary endpoint was objective response rate (ORR), and secondary endpoints were 3-year overall survival (OS), progression-free survival (PFS), larynx preservation rate (LPR), and metastasis-free survival (MFS). Patients (cT3-4aN0-2M0), regardless of sex, received induction chemoimmunotherapy for three cycles: camrelizumab 200 mg d1, docetaxel 75 mg/m

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHypopharyngeal NeoplasmsAdultAgedCisplatinFemaleHumansImmunotherapyInduction ChemotherapyMaleMiddle AgedNeoplasm StagingProgression-Free SurvivalTreatment OutcomeAntibodies, Monoclonal, HumanizedcamrelizumabCisplatin

Identifiers

PMID38898018
PMCPMC11187213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.